Clinical Trials 7 min 2024-10-28
Tirzepatide Shown to Improve Obstructive Sleep Apnea: SURMOUNT-OSA Results
The SURMOUNT-OSA trial demonstrated that tirzepatide significantly reduces sleep apnea severity, potentially offering an alternative to CPAP therapy for some patients.
Obstructive sleep apnea (OSA) affects approximately 30 million Americans, and obesity is the strongest risk factor. The SURMOUNT-OSA trial investigated whether tirzepatide-induced weight loss could improve this common and dangerous condition.
Study Design
Two complementary studies were conducted:
- Study 1: Patients with moderate-to-severe OSA not using CPAP
- Study 2: Patients with moderate-to-severe OSA using CPAP
- Both studies used tirzepatide 10 or 15 mg vs. placebo for 52 weeks
Key Results
Apnea-Hypopnea Index (AHI) Reduction
- Tirzepatide reduced AHI by approximately 50% (vs. ~5% with placebo)
- Many patients moved from severe to mild OSA categories
- Some patients achieved AHI levels below the diagnostic threshold for OSA
Weight Loss
- Average weight loss of approximately 18-20% of body weight
Quality of Life
- Significant improvements in daytime sleepiness scores
- Better sleep quality measures
- Improved oxygen saturation during sleep
Clinical Implications
These results suggest that tirzepatide could:
- Reduce or eliminate CPAP dependence for some patients
- Serve as a first-line treatment for obesity-related OSA
- Address the root cause of OSA (excess weight) rather than just treating symptoms
The FDA granted Breakthrough Therapy designation to tirzepatide for moderate-to-severe OSA, potentially leading to an additional approved indication.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before making any medical decisions.